Lavinia Costas: Division of Angiology, Department of Medicine II, Medical University and General Hospital of Vienna, Währinger Gürtel 18-20, Vienna, 1090, Austria.
Carsten Thilo Herz: Division of Angiology, Department of Medicine II, Medical University and General Hospital of Vienna, Währinger Gürtel 18-20, Vienna, 1090, Austria. ORCID
Clemens Höbaus: Division of Angiology, Department of Medicine II, Medical University and General Hospital of Vienna, Währinger Gürtel 18-20, Vienna, 1090, Austria. ORCID
Renate Koppensteiner: Division of Angiology, Department of Medicine II, Medical University and General Hospital of Vienna, Währinger Gürtel 18-20, Vienna, 1090, Austria.
Gerit-Holger Schernthaner: Division of Angiology, Department of Medicine II, Medical University and General Hospital of Vienna, Währinger Gürtel 18-20, Vienna, 1090, Austria. gerit.schernthaner@meduniwien.ac.at. ORCID
BACKGROUND: Oxidative stress is involved in cardiovascular disease such as peripheral artery disease (PAD). Vascular Peroxidase 1 (VPO1), a novel heme-containing peroxidase mainly expressed in the cardiovascular system, aggravates oxidative stress. Evidence in humans is limited. Current work aims to measure VPO1 in patients suffering from PAD, and to evaluate the association of VPO1 with conventional markers of cardiovascular risk factors (CVRF), including the estimated glomerular filtration rate (eGFR) and albuminuria categories. METHODS: This study is part of a longitudinal observational study. At baseline, 236 PAD-patients were included. VPO1 plasma levels (ng/mL) were measured by commercially available ELISA kits. A two-sided p level of < 0.05 was considered statistically significant. RESULTS: In the cross-sectional analysis (n = 236), VPO1 associated with ageing (p = 0.035) as well as with eGFR and albuminuria category, the markers of chronic kidney disease (CKD)-progression (p = 0.042). The longitudinal 18-months follow-up analysis (n = 152) demonstrated that baseline VPO1 predicts rapid kidney function decline (RKFD) (n = 49), defined as more than - 3 mL/min/1.73m eGFR loss per year, (OR per one SD VPO1 1.60 (1.11-2.30); p = 0.009). This association between VPO1 and kidney function withstood the multivariable adjustment for traditional CVRF including baseline eGFR and urine albumin-to-creatinine ratio (UACR), (adjOR per one SD VPO1 1.73 (1.14-2.61); p = 0.046). CONCLUSION: This study is first to reveal that VPO1 is independently associated with declining kidney function in patients with PAD. VPO1 shows a tighter association to kidney function than to other CVRF. This finding points to VPO1 as a potential target protein to assess CKD-progression.
